Tuesday, 17 November 2026 SEC EDGAR filings, as they land
ALFA USA News Straight from the SEC filing
SEC Filings
Regulatory Approval

CG Oncology Shares Surge 19% After 68 Percent Recurrence Risk Reduction in Phase 3 Trial

CG Oncology Reports 68 Percent Recurrence Risk Reduction in Phase 3 Bladder Cancer Trial

+19.62% $74.40 when we broke this story → $89.00 at 9:33 AM ET, 16 Nov 2026

CG Oncology announced that its Phase 3 PIVOT-006 registrational trial achieved its primary endpoint, demonstrating a 68% reduction in the risk of recurrence for bladder cancer patients. The positive topline results for cretostimogene grenadenorepvec support the company's plans for two separate Biologics License Application submissions in 2027.

Hallway, hospital, clean, rooms. Stock photo illustrating CG Oncology's regulatory approval story.
CG Oncology, Inc. · Healthcare · Photo: mspark0 / Pixabay

Key highlights

  • Achieved 68% reduction in the risk of recurrence compared to the control arm (Hazard Ratio 0.32)
  • Met primary endpoint in patients with intermediate-risk and high-grade Ta non-muscle invasive bladder cancer
  • Reported zero Grade 3 or higher treatment-related adverse events or discontinuations
  • Planned BLA submission for BCG-unresponsive NMIBC scheduled for March 2027
  • Anticipated second BLA filing for intermediate-risk and high-grade Ta NMIBC in Q2 2027

Clinical Outcomes and Safety Profile

CG Oncology announced that its PIVOT-006 Phase 3 registrational trial achieved its primary endpoint, showing a 68% reduction in the risk of recurrence for patients with intermediate-risk and high-grade Ta non-muscle invasive bladder cancer. The study, which evaluated adjuvant intravesical cretostimogene grenadenorepvec following complete tumor resection, demonstrated a hazard ratio of 0.32 with high statistical significance. Safety data remained consistent with previous studies, as the trial reported no Grade 3 or higher treatment-related adverse events and no discontinuations due to treatment-related issues during the median follow-up period of 17 months.

Regulatory Timeline and Strategy

The company is concurrently advancing its regulatory strategy, with plans to submit a Biologics License Application for cretostimogene in BCG-unresponsive NMIBC by March 2027. This submission will now include both patients with carcinoma in situ and those with high-grade papillary-only disease, effectively covering the full range of BCG-unresponsive cases. Additionally, a second BLA submission specifically for the intermediate-risk and high-grade Ta NMIBC population targeted in the PIVOT-006 trial is anticipated in the second quarter of 2027, following the completion of all necessary manufacturing activities supporting both regulatory filings.

Execution Milestone

“The unparalleled PIVOT-006 results represent a defining milestone for CG Oncology and position cretostimogene as the first and only therapeutic candidate to demonstrate a significant recurrence benefit in a pivotal Phase 3 trial in intermediate-risk and HG Ta NMIBC.”

Arthur Kuan, Chairman, President and Chief Executive Officer, CG Oncology

Business Overview and Market Opportunity

CG Oncology operates as a late-stage clinical biopharmaceutical company specializing in the development of oncolytic immunotherapies. Its lead candidate, cretostimogene, is an investigational oncolytic virus designed to selectively replicate in cancer cells and trigger an anti-tumor immune response. The company focus on NMIBC addresses a significant unmet need in the urology market, particularly for the estimated 50,000 patients in the United States who currently have no FDA-approved adjuvant treatment options for intermediate-risk and high-grade Ta disease, representing a substantial potential market expansion if the drug receives regulatory approval.

Financial and Technical Context

Following the clinical update, CG Oncology shares rose 6.06% to $74.40, resulting in a market capitalization of approximately $6.65 billion. The stock has demonstrated strong performance with a 20.31% gain over the last month, supported by a Relative Strength Index of 61.3. While the company is currently in the pre-commercial stage with annual revenue of $4.04 million, it maintains a robust pipeline focused on intravesical therapies. The successful Phase 3 data and defined BLA submission schedule provide a clear path toward commercial transition within the high-growth biotechnology sector.

CG Oncology, Inc. share price · last month
Line chart of CG Oncology, Inc.'s share price over the last month, from $59.96 on 19 Oct → $84.78 on 16 Nov; our story on 16 Nov at $74.40.

Up 14.0% since our story on 16 Nov: $74.40 when we broke it → $84.78 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.

Show the prices
19 Oct$59.96
20 Oct$61.93
21 Oct$62.24
22 Oct$62.54
23 Oct$61.71
26 Oct$61.56
27 Oct$62.94
28 Oct$63.96
29 Oct$63.47
30 Oct$64.68
2 Nov$61.96
3 Nov$64.06
4 Nov$67.71
5 Nov$64.80
6 Nov$75.99
9 Nov$74.74
10 Nov$72.64
11 Nov$72.61
12 Nov$70.15
13 Nov$74.40
16 Nov$84.78

Management commentary

“Today’s results highlight our differentiated clinical approach, aimed at exploring cretostimogene across the broad NMIBC spectrum and build upon our robust body of clinical evidence including what we believe to be the best-in-disease safety and tolerability data reported.”

Vijay Kasturi, M.D., Chief Medical Officer, CG Oncology
CG Oncology, Inc. · financial snapshot
Share price$74.40
Market cap$6.6B
Revenue (annual)$4M
1-month price change+20.31%
SectorHealthcareBiotechnology

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.

Source verified

SEC filing by CG Oncology, Inc. announcing topline results from the PIVOT-006 Phase 3 trial.

Read the filing ↗

Track CG Oncology, Inc. live

Get the next CG Oncology, Inc. SEC filing seconds after it lands.

More in Approvals

All →

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.